Thrivewell Infusion, which notched a minority investment from TZP Group late last year, is close to completing its first acquisition, CEO Ben Neuberg tells Axios exclusively.
Why it matters: Over its seven-year trajectory, Thrivewell has employed a solely de-novo growth strategy — which most investors see as preferable.
